INNOVATIVE PUBLICATION
Journal of Effective Learning and Sustainable Innovation
Vol.3 №4 (2025). April
innovativepublication.uz

GUIDELINES FOR THE RATIONAL USE OF BRONCHODILATORS IN CHILDREN UNDER 3 YEARS OF AGE

Usmonova Feruza Tokhirjonovna
Assistant, Department of Pharmacology, Clinical Pharmacology and Medical Biotechnology, ASMI

Abstract: This article presents a critical overview of the rational use of bronchodilators in children under three years of age. It addresses the pharmacological basis, clinical indications, administration methods, and safety considerations specific to this vulnerable age group. Drawing on international pediatric guidelines, the paper emphasizes evidence-based prescribing, individualized risk-benefit assessment, and the need to avoid overtreatment in cases of nonspecific wheezing. The aim is to provide a structured framework for optimizing respiratory care while minimizing adverse outcomes.

Keywords: Bronchodilators, pediatric asthma, wheezing, infants, beta-agonists, anticholinergics, nebulization, evidence-based pediatrics.

INTRODUCTION

Respiratory illnesses are among the most common reasons for medical consultations and hospitalizations in children under three years of age. Bronchodilators, particularly short-acting beta-agonists (SABAs) such as salbutamol (albuterol), are frequently used to manage episodes of wheezing and suspected bronchospasm. However, the clinical utility of bronchodilators in infants and toddlers remains a subject of ongoing debate due to the high prevalence of transient or viral-induced wheezing in this age group and the low rate of true asthma diagnoses before age three. Consequently, the rational use of bronchodilators in

young children requires a nuanced understanding of respiratory pathophysiology, developmental pharmacology, and age-specific treatment responses. This article outlines current guidelines and expert consensus on when, how, and in whom bronchodilators should be used effectively and safely in children under three years old.

MATERIALS AND METHODS

The use of bronchodilators in children under the age of three must be based on clearly defined clinical criteria, as wheezing in this age group is often multifactorial and not always responsive to beta-agonist therapy. Common causes include viral bronchiolitis, transient early wheezing, structural airway anomalies, and, less frequently, early-onset asthma. It is essential to distinguish between these etiologies because not all are responsive to bronchodilators. The Global Initiative for Asthma (GINA) and American Academy of Pediatrics (AAP) advise against routine use of bronchodilators in bronchiolitis, the most common cause of wheezing in infants, citing multiple clinical trials that demonstrate minimal to no benefit in reducing symptom duration, oxygen requirement, or hospitalization rates.

Nevertheless, bronchodilators may have a role in select cases. For example, in infants with a strong family history of atopy, eczema, or parental asthma — or those who exhibit clear, repeated responsiveness to bronchodilator therapy — a therapeutic trial may be justified. In such instances, a short-acting beta-agonist delivered via metered-dose inhaler (MDI) with a spacer and face mask is preferred over nebulization, due to better dose control, shorter administration time, and lower systemic absorption. The recommended SABA dose for infants is typically 100–200 mcg (1–2 puffs) every 4–6 hours as needed, not exceeding six doses per day unless under close medical supervision.

RESULTS AND DISCUSSION

Long-acting beta-agonists (LABAs) and oral bronchodilators are generally contraindicated in children under three due to insufficient safety data, risk of tachycardia,

tremors, and potential for paradoxical bronchospasm. Similarly, ipratropium bromide, a short-acting anticholinergic, may be used in combination with SABA in emergency settings for moderate to severe exacerbations, but is not recommended for routine outpatient use in this age group.

An important principle in rational prescribing is therapeutic response monitoring. Any bronchodilator trial in children under three should be accompanied by careful observation of clinical indicators such as reduced wheezing, improved respiratory rate, normalized oxygen saturation, and feeding tolerance. If no clear improvement is seen within 24 to 48 hours, the medication should be discontinued. Prolonged or empirical use of bronchodilators in non-responsive wheezing can expose the child to unnecessary side effects, delay accurate diagnosis, and increase caregiver anxiety.

The method of administration also plays a crucial role in achieving therapeutic benefit. MDIs with valved holding chambers (spacers) and tight-fitting face masks have been shown to be as effective as nebulizers and more convenient for home use. Proper caregiver education on inhaler technique, dosing schedule, and recognition of adverse effects (such as jitteriness, sleep disturbance, or vomiting) is a cornerstone of safe and effective treatment.

In situations where bronchodilators are part of a broader asthma management plan — typically in children with recurrent episodes of wheezing, poor growth, or hospitalization history — pediatric asthma specialists may introduce maintenance therapy using inhaled corticosteroids (ICS) alongside intermittent bronchodilator use. However, this approach is reserved for well-documented cases and should not be initiated without thorough diagnostic workup and follow-up [1].

Lastly, clinicians must be vigilant in recognizing red flags that suggest underlying pathology requiring specialist referral. These include persistent wheeze not responsive to bronchodilators, stridor, failure to thrive, nocturnal symptoms, or radiographic

abnormalities. In such cases, continued bronchodilator use without diagnosis may be not only ineffective but harmful.

An often underappreciated aspect in the rational use of bronchodilators among children under three is the unique pharmacokinetic and pharmacodynamic profile of this age group. Infants and toddlers exhibit substantial physiological differences compared to older children and adults — including immature hepatic metabolism, variable airway receptor expression, and higher lung compliance — all of which can alter drug absorption, distribution, and response. These differences may result in either subtherapeutic effects or, conversely, exaggerated systemic responses even at standard pediatric dosages. For example, immature β_2-adrenergic receptor function in the peripheral airways may partially explain the limited bronchodilatory response in certain infants despite appropriate dosing. Hence, drug selection and titration in this population must be approached with particular caution and clinical judgment [2].

Several randomized controlled trials and systematic reviews have evaluated bronchodilator efficacy in common early childhood conditions, most notably acute viral bronchiolitis — a major cause of wheezing in this age group. The majority of high-quality studies, including Cochrane analyses, have consistently failed to demonstrate sustained clinical improvement in respiratory parameters or hospitalization duration with the routine use of salbutamol or other β_2-agonists in bronchiolitis. This lack of consistent benefit contrasts sharply with clinical practices in many healthcare settings, where bronchodilators are still prescribed liberally. The discrepancy reflects a broader tension between evidence-based medicine and the pressures of real-world clinical decision-making, including caregiver expectations, institutional norms, and the diagnostic uncertainty surrounding pediatric respiratory illnesses [3].

Another layer of complexity arises from the ethical considerations surrounding off-label use. Many bronchodilators used in children under three — including inhaled

ipratropium bromide and, historically, oral theophylline — lack robust pediatric-specific regulatory approval due to limited age-targeted trials. Clinicians are therefore often faced with the challenge of weighing potential benefits against poorly defined risks when using such agents. While off-label prescribing is legally permissible and sometimes medically appropriate, it places a greater onus on clinicians to base their decisions on high-quality evidence, shared decision-making with caregivers, and thorough documentation.

Geographic and socioeconomic disparities also influence the rational use of bronchodilators in this age group. In low-resource settings, where access to diagnostic tools such as pulse oximetry or pediatric pulmonology consultation is limited, bronchodilator therapy is sometimes initiated as a default measure. Conversely, in tertiary-care centers equipped with guideline protocols and multidisciplinary oversight, bronchodilator use is generally more aligned with evidence-based thresholds. Furthermore, the availability of spacers, MDI devices, and caregiver training infrastructure often determines whether bronchodilators are administered correctly — a factor that directly affects both efficacy and safety [4].

Health system-level interventions, such as standardized treatment algorithms and quality improvement initiatives, have shown promise in reducing inappropriate bronchodilator use in pediatric emergency and inpatient settings. For instance, hospitals that implement decision support systems embedded in electronic medical records, along with staff education campaigns, report significant reductions in unnecessary bronchodilator administration without adversely affecting clinical outcomes. Such strategies exemplify how rational pharmacotherapy in infants extends beyond individual prescribing to systemic policy design and accountability mechanisms [5].

Lastly, cultural perceptions of respiratory distress and medication often drive caregiver demand, creating pressure on clinicians to prescribe “something” even when objective benefit is doubtful. In some cultures, audible wheezing is interpreted as a

dangerous sign requiring aggressive intervention, regardless of its etiology or pathophysiology. In these situations, clinician communication skills — especially the ability to explain the self-limiting nature of many wheezing episodes and the rationale for conservative management — become central to ensuring rational drug use.

CONCLUSION

The rational use of bronchodilators in children under three years of age demands cautious, evidence-based decision-making. While short-acting beta-agonists may be beneficial in selected clinical scenarios, routine use in viral wheezing or bronchiolitis is not supported by current evidence. Accurate diagnosis, short-duration therapeutic trials, caregiver education, and avoidance of unnecessary polypharmacy are essential principles in minimizing harm and maximizing benefit. As research continues to evolve, adherence to updated clinical guidelines will help ensure bronchodilators are used responsibly in this sensitive population.

REFERENCES:

1. American Academy of Pediatrics. Diagnosis and Management of Bronchiolitis. – Pediatrics. – 2014. – Vol. 134, №5. – P. e1474–e1502.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention – Updated 2023. – [Online resource]. – URL: https://ginasthma.org
3. Everard, M. L., Milner, A. D. The Use of Beta-Agonists in Preschool Children. – Pediatr Pulmonol. – 2006. – Vol. 41, №11. – P. 1053–1062.
4. Gadomski, A. M., Scribani, M. Evidence-Based Review of the Effectiveness of Bronchodilators for Bronchiolitis. – Pediatrics. – 2014. – Vol. 131, №4. – P. 585–595.
5. Turner, S. The use of inhaled bronchodilators in infants: What is the evidence? – Paediatr Respir Rev. – 2015. – Vol. 16, №2. – P. 92–98.